# Telix Pharmaceuticals

Source: https://onco.cc/companies/telix/  
OnCo record `telix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.

## Summary

Telix Pharmaceuticals, based in Melbourne and listed as TLX.AX, is the Australian theranostics company behind the Illuccix and Gozellix kits for gallium-68 PSMA-11 imaging and a broad therapeutic pipeline. TLX250-CDx, or zirconium-89 girentuximab for carbonic anhydrase IX PET in kidney cancer, received an FDA complete response letter in 2025, TLX591, or lutetium-177 rosopatamab, a PSMA antibody in the ProstACT phase 3, and TLX101 for glioma follow. OnCo links it to prostate cancer and renal cell carcinoma, to PSMA as a target, to CAIX PET and PET tracer manufacturing, and to the idea of CAIX theranostics pairing girentuximab imaging with lutetium or actinium therapy. Whether an antibody-based PSMA therapy can compete with small-molecule ligands is the open question. Illuccix has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Melbourne
- Type: radiopharma
- Website: https://telixpharma.com
- Ticker: TLX.AX

## Sources

- Official website: https://telixpharma.com

## Connected records

- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- drugs: [Gallium-68 gozetotide (PSMA-11)](https://onco.cc/drugs/ga68-psma-11/), [Illuccix (kit for Ga-68 gozetotide)](https://onco.cc/drugs/illuccix/), [Zirconium-89 girentuximab](https://onco.cc/drugs/girentuximab-zr89/)
- trials: [89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study](https://onco.cc/trials/nct06750419/), [89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study](https://onco.cc/trials/nct03849118/), [PSMA PET Combined With MRI for the Detection of PCa](https://onco.cc/trials/nct07052214/), [Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma](https://onco.cc/trials/nct07100730/), [The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)](https://onco.cc/trials/nct06520345/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [CAIX PET (89Zr-girentuximab)](https://onco.cc/technologies/caix-pet/), [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://onco.cc/technologies/cyclotron-isotope-production/), [PET tracer manufacturing and distribution](https://onco.cc/technologies/pet-tracer-manufacturing/), [Radionuclide generators and cold kits](https://onco.cc/technologies/radionuclide-generators-kits/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/)
- ideas: [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://onco.cc/ideas/idea-caix-theranostics/)

---
JSON: https://onco.cc/api/v1/entities/telix.json